Selected research
Industry Growth & Trends
Global Viral Gene Therapy Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Viral Gene Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Viral Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Viral Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Viral Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Viral Gene Therapy market include AnGes, Catalent, Ionis Pharmaceuticals, Orchard Therapeutics, Sarepta Therapeutics, SIBIONO, Spark Therapeutics, Amgen and Biogen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Viral Gene Therapy market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Viral Gene Therapy market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Viral Gene Therapy market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Viral Gene Therapy.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Viral Gene Therapy market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Viral Gene Therapy Market by Company
AnGes
Catalent
Ionis Pharmaceuticals
Orchard Therapeutics
Sarepta Therapeutics
SIBIONO
Spark Therapeutics
Amgen
Biogen
Gilead Sciences
Lonza
Novartis
Shanghai Sunway Biotech
Viral Gene Therapy Segment by Type
Integrating Viral Vectors
Non-Integrating Viral Vectors
Viral Gene Therapy Segment by Application
Ophthalmologic Diseases
Hematologic Diseases
Cardiovascular Diseases
Muscular Diseases
Metabolic Diseases
Infectious Diseases
Others
Viral Gene Therapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Viral Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Gene Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Viral Gene Therapy companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Integrating Viral Vectors
- Non-Integrating Viral Vectors
Applications
- Ophthalmologic Diseases
- Hematologic Diseases
- Cardiovascular Diseases
- Muscular Diseases
- Metabolic Diseases
- Infectious Diseases
- Others
Companies covered
- AnGes
- Catalent
- Ionis Pharmaceuticals
- Orchard Therapeutics
- Sarepta Therapeutics
- SIBIONO
- Spark Therapeutics
- Amgen
- Biogen
- Gilead Sciences
- Lonza
- Novartis
- Shanghai Sunway Biotech
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Viral Gene Therapy Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Viral Gene Therapy Market Size by Region (2021-2032)
- 1.4.1 Global Viral Gene Therapy Market Size by Region (2021-2026)
- 1.4.2 Global Viral Gene Therapy Market Size by Region (2027-2032)
- 1.5 Key Regions Viral Gene Therapy Market Size (2021-2032)
- 1.5.1 North America Viral Gene Therapy Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Viral Gene Therapy Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Viral Gene Therapy Market Size Growth Rate (2021-2032)
- 1.5.4 South America Viral Gene Therapy Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Viral Gene Therapy Market Size Growth Rate (2021-2032)
2 Viral Gene Therapy Market by Type
- 2.1 Type Introduction
- 2.1.1 Integrating Viral Vectors
- 2.1.2 Non-Integrating Viral Vectors
- 2.2 Global Viral Gene Therapy Market Size by Type
- 2.2.1 Global Viral Gene Therapy Market Size Overview by Type (2021-2032)
- 2.2.2 Global Viral Gene Therapy Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Viral Gene Therapy Market Size Forecasted by Type (2027-2032)
- 2.3 Global Viral Gene Therapy Market Size by Regions
- 2.3.1 North America Viral Gene Therapy Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Viral Gene Therapy Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Viral Gene Therapy Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Viral Gene Therapy Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Viral Gene Therapy Market Size Breakdown by Type (2021-2026)
3 Viral Gene Therapy Market by Application
- 3.1 Type Introduction
- 3.1.1 Ophthalmologic Diseases
- 3.1.2 Hematologic Diseases
- 3.1.3 Cardiovascular Diseases
- 3.1.4 Muscular Diseases
- 3.1.5 Metabolic Diseases
- 3.1.6 Infectious Diseases
- 3.1.7 Others
- 3.2 Global Viral Gene Therapy Market Size by Application
- 3.2.1 Global Viral Gene Therapy Market Size Overview by Application (2021-2032)
- 3.2.2 Global Viral Gene Therapy Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Viral Gene Therapy Market Size Forecasted by Application (2027-2032)
- 3.3 Global Viral Gene Therapy Market Size by Regions
- 3.3.1 North America Viral Gene Therapy Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Viral Gene Therapy Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Viral Gene Therapy Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Viral Gene Therapy Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Viral Gene Therapy Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Viral Gene Therapy Industry Trends
- 4.2 Viral Gene Therapy Industry Drivers
- 4.3 Viral Gene Therapy Industry Opportunities and Challenges
- 4.4 Viral Gene Therapy Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Viral Gene Therapy Revenue (2021-2026)
- 5.2 Global Viral Gene Therapy Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Viral Gene Therapy Key Company Headquarters & Area Served
- 5.4 Global Viral Gene Therapy Company, Product Type & Application
- 5.5 Global Viral Gene Therapy Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Viral Gene Therapy Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Viral Gene Therapy Players Market Share by Revenue in 2025
- 5.6.3 2025 Viral Gene Therapy Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 AnGes
- 6.1.1 AnGes Company Information
- 6.1.2 AnGes Business Overview
- 6.1.3 AnGes Viral Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 AnGes Viral Gene Therapy Product Portfolio
- 6.1.5 AnGes Recent Developments
- 6.2 Catalent
- 6.2.1 Catalent Company Information
- 6.2.2 Catalent Business Overview
- 6.2.3 Catalent Viral Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Catalent Viral Gene Therapy Product Portfolio
- 6.2.5 Catalent Recent Developments
- 6.3 Ionis Pharmaceuticals
- 6.3.1 Ionis Pharmaceuticals Company Information
- 6.3.2 Ionis Pharmaceuticals Business Overview
- 6.3.3 Ionis Pharmaceuticals Viral Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Ionis Pharmaceuticals Viral Gene Therapy Product Portfolio
- 6.3.5 Ionis Pharmaceuticals Recent Developments
- 6.4 Orchard Therapeutics
- 6.4.1 Orchard Therapeutics Company Information
- 6.4.2 Orchard Therapeutics Business Overview
- 6.4.3 Orchard Therapeutics Viral Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Orchard Therapeutics Viral Gene Therapy Product Portfolio
- 6.4.5 Orchard Therapeutics Recent Developments
- 6.5 Sarepta Therapeutics
- 6.5.1 Sarepta Therapeutics Company Information
- 6.5.2 Sarepta Therapeutics Business Overview
- 6.5.3 Sarepta Therapeutics Viral Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Sarepta Therapeutics Viral Gene Therapy Product Portfolio
- 6.5.5 Sarepta Therapeutics Recent Developments
- 6.6 SIBIONO
- 6.6.1 SIBIONO Company Information
- 6.6.2 SIBIONO Business Overview
- 6.6.3 SIBIONO Viral Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 SIBIONO Viral Gene Therapy Product Portfolio
- 6.6.5 SIBIONO Recent Developments
- 6.7 Spark Therapeutics
- 6.7.1 Spark Therapeutics Company Information
- 6.7.2 Spark Therapeutics Business Overview
- 6.7.3 Spark Therapeutics Viral Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Spark Therapeutics Viral Gene Therapy Product Portfolio
- 6.7.5 Spark Therapeutics Recent Developments
- 6.8 Amgen
- 6.8.1 Amgen Company Information
- 6.8.2 Amgen Business Overview
- 6.8.3 Amgen Viral Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Amgen Viral Gene Therapy Product Portfolio
- 6.8.5 Amgen Recent Developments
- 6.9 Biogen
- 6.9.1 Biogen Company Information
- 6.9.2 Biogen Business Overview
- 6.9.3 Biogen Viral Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Biogen Viral Gene Therapy Product Portfolio
- 6.9.5 Biogen Recent Developments
- 6.10 Gilead Sciences
- 6.10.1 Gilead Sciences Company Information
- 6.10.2 Gilead Sciences Business Overview
- 6.10.3 Gilead Sciences Viral Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Gilead Sciences Viral Gene Therapy Product Portfolio
- 6.10.5 Gilead Sciences Recent Developments
- 6.11 Lonza
- 6.11.1 Lonza Company Information
- 6.11.2 Lonza Business Overview
- 6.11.3 Lonza Viral Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Lonza Viral Gene Therapy Product Portfolio
- 6.11.5 Lonza Recent Developments
- 6.12 Novartis
- 6.12.1 Novartis Company Information
- 6.12.2 Novartis Business Overview
- 6.12.3 Novartis Viral Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Novartis Viral Gene Therapy Product Portfolio
- 6.12.5 Novartis Recent Developments
- 6.13 Shanghai Sunway Biotech
- 6.13.1 Shanghai Sunway Biotech Company Information
- 6.13.2 Shanghai Sunway Biotech Business Overview
- 6.13.3 Shanghai Sunway Biotech Viral Gene Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Shanghai Sunway Biotech Viral Gene Therapy Product Portfolio
- 6.13.5 Shanghai Sunway Biotech Recent Developments
7 North America
- 7.1 North America Viral Gene Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Viral Gene Therapy Market Size by Country (2021-2026)
- 7.3 North America Viral Gene Therapy Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Viral Gene Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Viral Gene Therapy Market Size by Country (2021-2026)
- 8.3 Europe Viral Gene Therapy Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Viral Gene Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Viral Gene Therapy Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Viral Gene Therapy Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Viral Gene Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Viral Gene Therapy Market Size by Country (2021-2026)
- 10.3 South America Viral Gene Therapy Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Viral Gene Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Viral Gene Therapy Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Viral Gene Therapy Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst